The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan.
| Autor: | Masuno S; Makinohara Nanohana Otorhinolaryngology Clinic, Chiba, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Acta oto-laryngologica [Acta Otolaryngol] 2024 Jul-Aug; Vol. 144 (7-8), pp. 467-475. Date of Electronic Publication: 2024 Sep 12. |
| DOI: | 10.1080/00016489.2024.2397054 |
| Abstrakt: | Background: Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases. Aims/objectives: To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions. Material and Methods: In total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis ( n = 72), house dust mite allergy ( n = 55), or both ( n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated. Results: The three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE ® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE ® patients with seven or more positive antigen types. Conclusions and Significance: Severe adverse reactions reduced early adherence. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|